TF and neoplasm: In the last decade, new strategies have been developed for targeting oncogenic and rescuing tumor-suppressive TF functions, modulating their expression or degradation by blocking protein/protein interactions, and preventing its DNA binding either through a binding pocket or at the DNA-interacting site; some of these inhibitors are currently being used or evaluated for cancer treatment [180].